NewAmsterdam Pharma Co N.V. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q1 2023 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
NewAmsterdam Pharma Co N.V. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q1 2023 to Q2 2024.
- NewAmsterdam Pharma Co N.V. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was -$39M, a 1.87% decline year-over-year.
- NewAmsterdam Pharma Co N.V. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$177M, a 682% decline from 2022.
- NewAmsterdam Pharma Co N.V. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$22.6M, a 45.8% increase from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)